Mean Beck Depression Inventory-II Scores of Outpatients with Dysthymic or Recurrent-Episode Major Depressive Disorders

2003 ◽  
Vol 93 (2) ◽  
pp. 507-512 ◽  
Author(s):  
Roberta Ball ◽  
Robert A. Steer
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Beck Depression Inventory ◽  
Depressive Disorders ◽  
Recurrent Episode ◽  
Dysthymic Disorder ◽  
Major Depressive ◽  
Major Depressive Disorders ◽  
The Mean ◽  
Comorbid Depressive Disorder

The Beck Depression Inventory-II, published in 1996, was administered to 100 adult outpatients (Age M = 43.1 yr., SD = 15.6) who were diagnosed with a recurrent-episode Major Depressive Disorder and 100 outpatients (Age M = 42.8 yr., SD = 15.7) who were diagnosed with a Dysthymic Disorder. Each diagnostic group was composed of 50 men and 50 women who did not have a comorbid depressive disorder. The mean Beck Depression Inventory-II total score and the mean number of symptoms endorsed by the outpatients with a Major Depressive Disorder were significantly (ps < .001) higher than those for outpatients with a Dysthymic Disorder. The usefulness of the Beck Depression Inventory–II was discussed in helping clinicians discriminate between these two unipolar disorders.

scholarly journals Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions – Improvement (CGI-S) scale in bipolar and major depressive disorder

2018 ◽  
Vol 53 ◽  
pp. 17-22 ◽  
Author(s):  
M. Mohebbi ◽  
S. Dodd ◽  
O.M. Dean ◽  
M. Berk
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Convergent Validity ◽  
Depressive Disorders ◽  
Symptom Improvement ◽  
Major Depressive ◽  
Global Improvement ◽  
Patient Global Impression ◽  
Major Depressive Disorders ◽  
Patient Centric

AbstractBackground:Concordant with an increased emphasis on consumer engagement, the Patient Global Impression Scale of Improvement (PGI-I) is commonly used as an outcome measure in studies evaluating the efficacy of treatments in medical and psychiatric conditions with subjective symptom domains. The current study evaluated the agreement between PGI-I and Clinician Global Impression Scale of Improvement (CGI-I) ratings and convergent validity of PGI-I among individuals with bipolar or major depressive disorders.Method:Data were derived from three double-blind, placebo-controlled, multicentre studies conducted from 2007 to 2015 among adult individuals (N = 472). Clinicians were asked to rate participants symptoms using the CGI-I as well as severity of depression by the Montgomery-Åsberg Depression (MADRS), quality of life (Q-LES-Q), social and occupational functioning (SOFAS), and functional impairment (LIFE–RIFT). Participants were asked to assess their symptom improvement with the PGI-I. Bland-Altman agreement plots and Intra-class correlations were used to evaluate agreement, and Spearman correlation coefficients were implemented to examine convergent validity. Sub-group analyses for disorder type (bipolar and major depression) were performed.Results:There was high agreement between the PGI-I and CGI-I ratings across follow-up time points (weeks 2, 4, 6, 8, 12, 16, 20, 24, and 28). Similar results were observed in male only and female only data and after adjustment for age and gender. Both PGI-I and CGI-I ratings were robustly positively correlated with MADRS, and LIFE-RIFT and negatively correlated with SOFAS and Q-LES-Q, supporting the convergent validity of the PGI-I. Sub-group analyses for bipolar and major depressive disorder showed similar findings.Conclusion:Our findings support the utility of the PGI-I as a participant rated measure of global improvement among individuals with bipolar or major depressive disorders.

scholarly journals COVID-19 related lockdown: a trigger from the pre-melancholic phase to catatonia and depression, a case report of a 59 year-old man

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Giuseppe Sarli ◽  
Lorenzo Polidori ◽  
David Lester ◽  
Maurizio Pompili
Keyword(s):  
Major Depressive Disorder ◽  
Case Report ◽  
Depressive Disorder ◽  
Depressive Disorders ◽  
Personality Structure ◽  
Major Depressive ◽  
Psychological Implication ◽  
Major Depressive Disorders ◽  
Psychotic Behavior ◽  
Desire To Die

Abstract Background The pre-melancholic model described by Tellenbach may provide a common model for understanding the psychological implications of the lockdown. In this case report, we describe a rare catatonic status as a psychological implication linked to the COVID-19 pandemic, a really unique global situation. Case presentation B is a 59 year-old man with mute psychiatric anamnesis whose mother suffered from a major depressive disorder. As the lockdown began, he started to develop concerns about his family’s economic condition. According to his wife, he could see no end to the epidemic and no future at all. Moving from this, he started to show a severe and rapidly progressive depression and to develop mood congruent delusions. In addition, he had increasing anhedonia, apathy, starvation and insomnia. This turned in the end into a catatonic-like state, along with a deep desire to die. Admitted to the psychiatry ward in a state of mutism, he was discharged after 15 days with a diagnosis of “Major depressive disorder, single severe episode with no psychotic behavior”. He was treated with Sertraline, Olanzapine and Lorazepam. Conclusions Our aim is to draw attention to the effect of the lockdown upon a Tellenbach-like personality structure. Identifying this type of pre-morbid personality structure could help clinicians understand and treat some cases of patients with severe major depressive disorders elicited by the COVID-19 pandemic.

scholarly journals Depressive Disorders

Psychology ◽  
2015 ◽  
Author(s):  
Lawrence P. Riso ◽  
Matthew Vaughn
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Early Onset ◽  
Depressive Disorders ◽  
Dysthymic Disorder ◽  
World Health ◽  
Major Depressive ◽  
High Prevalence ◽  
Health Organization ◽  
Persistent Depressive Disorder

Depression is distinguished from ordinary sadness by its greater duration, severity, and impact on functioning. It is a highly prevalent condition, often with an early onset. Nearly a quarter of all individuals will experience a diagnosable depression at some point in their lifetimes. The early onset and recurrent nature of depression contribute to making it the most burdensome illness in the entire world, according to the World Health Organization. Over the last thirty years, the diagnosis of depression has changed little. Since 1980, every edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) has included a category for severe acute depression (i.e., “major depression” or “major depressive disorder”) and a category for chronic depression (i.e., “dysthymia,” “dysthymic disorder,” or “persistent depressive disorder”). The current edition of the DSM (DSM-5) includes two main categories, “major depressive disorder” and “persistent depressive disorder.” Owing, perhaps, to its high prevalence rate and societal impact, depression is very well studied.

scholarly journals Haematological and Haemostatic Changes Associated with Major Depressive Disorder among Nigerians.

2021 ◽  
Vol 5 (2) ◽  
pp. 238-245
Author(s):  
Oloruntoba A. Ekun
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Sodium Citrate ◽  
Red Cell ◽  
Major Depressive ◽  
Red Cell Indices ◽  
Healthy Control ◽  
The Mean ◽  
Number Of Individuals ◽  
Apparently Healthy

Background: A link between major depressive disorder (MDD) and haematological as well as co-agulation disorders has been postulated. This study aims to evaluate haematological and haemostatic changes among Nigerians with major depressive disorder Methods: Two hundred volunteers consisting of an equal number of individuals diagnosed with major depressive disorder (MDD) based on DMS-IV criteria and apparently healthy control participated in this study. The blood sample was collected into tri-sodium citrate K2EDTA bottles respectively and was evaluated for some haemostatic parameters , using ELISA, Clauss, Quick’s One Stage, Proctor and Rapaport’s methods. Results: The mean WBC, hemoglobin and differential lymphocyte were significantly higher among MDD total volunteers (p < 0.001). The red cell indices and platelet count were lower among MDD (p <0.001). Also the prothrombin time (PT), fibrinogen, protein-C and erythrocytes sedimentation rate (ESR) were all raised (p <0.001) among volunteers with MDD. Positive associations existed be-tween MCV and RBC (r: 0.364; p<0.001), PT and APTT (r: 0.319 p <0.001), APTT and fibrinogen (r: 0.239, p = 0.017) as well as PT and fibrinogen (r: 0.275 p = 0.006) at 95% confidence interval. Conclusion: Changes in total leucocytes count, lymphocytes values and haemostatic parameters among volunteers with depression may impacts deleterious effects on the immune response as well as haemostatic homeostasis, while decreased red cell indices may suggest occult nutritional anaemia.

The Unified Protocol for Major Depressive Disorder

2017 ◽  
pp. 67-85
Author(s):  
James F. Boswell ◽  
Laren R. Conklin ◽  
Jennifer M. Oswald ◽  
Matteo Bugatti
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Emotional Disorders ◽  
Clinical Case ◽  
Depressive Disorders ◽  
Major Depressive ◽  
Transdiagnostic Treatment ◽  
Unified Protocol ◽  
High Level ◽  
Future Work

Major depressive disorder (MDD) can be a chronic, debilitating condition that for many individuals waxes and wanes over time. In addition, MDD and other unipolar depressive disorders demonstrate a high level of comorbidity with anxiety disorders. This chapter describes the application of the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) to MDD and other unipolar depressive disorders. We first review research supporting the association between depression and higher-order constructs such as neuroticism. Next, we present a clinical case that, combined with module-specific recommendations, further illustrates how UP principles and strategies are implemented in the treatment of primary depression. Finally, we offer recommendations for future work involving the UP for major depression and other depressive disorders.

A further assessment of decision-making in anorexia nervosa

2015 ◽  
Vol 30 (1) ◽  
pp. 121-127 ◽  
Author(s):  
C. Adoue ◽  
I. Jaussent ◽  
E. Olié ◽  
S. Beziat ◽  
F. Van den Eynde ◽  
...  
Keyword(s):  
Decision Making ◽  
Major Depressive Disorder ◽  
Anorexia Nervosa ◽  
Depressive Disorder ◽  
Cognitive Processes ◽  
Depressive Disorders ◽  
Iowa Gambling Task ◽  
Learning Task ◽  
Adult Women ◽  
Major Depressive

AbstractObjective:Anorexia nervosa (AN) may be associated with impaired decision-making. Cognitive processes underlying this impairment remain unclear, mainly because previous assessments of this complex cognitive function were completed with a single test. Furthermore, clinical features such as mood status may impact this association. We aim to further explore the hypothesis of altered decision-making in AN.Method:Sixty-three adult women with AN and 49 female controls completed a clinical assessment and were assessed by three tasks related to decision-making [Iowa Gambling Task (IGT), Balloon Analogue Risk Task (BART), Probabilistic Reversal Learning Task (PRLT)].Results:People with AN had poorer performance on the IGT and made less risky choices on the BART, whereas performances were not different on PRLT. Notably, AN patients with a current major depressive disorder showed similar performance to those with no current major depressive disorder.Conclusion:These results tend to confirm an impaired decision making-process in people with AN and suggest that various cognitive processes such as inhibition to risk-taking or intolerance of uncertainty may underlie this condition Furthermore, these impairments seem unrelated to the potential co-occurent major depressive disorders.

Plasma glial cell line-derived neurotrophic factor in patients with major depressive disorder: a preliminary study

2015 ◽  
Vol 28 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Bun-Hee Lee ◽  
Jin-Pyo Hong ◽  
Jung-A Hwang ◽  
Kyoung-Sae Na ◽  
Won-Joong Kim ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cell Line ◽  
Glial Cell ◽  
Neurotrophic Factor ◽  
Recurrent Episode ◽  
First Episode ◽  
Healthy Controls ◽  
Major Depressive ◽  
Before And After

BackgroundSome clinical studies have reported reduced peripheral glial cell line-derived neurotrophic factor (GDNF) level in elderly patients with major depressive disorder (MDD). We verified whether a reduction in plasma GDNF level was associated with MDD.MethodPlasma GDNF level was measured in 23 healthy control subjects and 23 MDD patients before and after 6 weeks of treatment.ResultsPlasma GDNF level in MDD patients at baseline did not differ from that in healthy controls. Plasma GDNF in MDD patients did not differ significantly from baseline to the end of treatment. GDNF level was significantly lower in recurrent-episode MDD patients than in first-episode patients before and after treatment.ConclusionsOur findings revealed significantly lower plasma GDNF level in recurrent-episode MDD patients, although plasma GDNF levels in MDD patients and healthy controls did not differ significantly. The discrepancy between our study and previous studies might arise from differences in the recurrence of depression or the ages of the MDD patients.

Sign in / Sign up

Export Citation Format

Share Document